This study is to evaluate the efficacy and safety of PLS240 in patients with
hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism
(SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase
where patients will be randomly assigned to either receive dose-titrated PLS240 or matching
placebo for 27 weeks. After the completion of the double-blind phase, patients will be
eligible to enroll in the open-label extension phase, where they will receive dose-titrated
PLS240 for an additional 26 weeks. Throughout the duration of the study, patients will be
expected to attend multiple study visits where an investigator will collect blood, preform
electrocardiograms (ECGs) and physical exams, and further assess the safety and efficacy of
PLS240.